ATE491723T1 - Neue verbindungen mit gemischter amylin aktivität - Google Patents

Neue verbindungen mit gemischter amylin aktivität

Info

Publication number
ATE491723T1
ATE491723T1 AT99906782T AT99906782T ATE491723T1 AT E491723 T1 ATE491723 T1 AT E491723T1 AT 99906782 T AT99906782 T AT 99906782T AT 99906782 T AT99906782 T AT 99906782T AT E491723 T1 ATE491723 T1 AT E491723T1
Authority
AT
Austria
Prior art keywords
treating
diabetes
amylin
compounds
type
Prior art date
Application number
AT99906782T
Other languages
English (en)
Inventor
Nigel Beeley
Kathryn Prickett
Kevin Beaumont
Original Assignee
Amylin Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amylin Pharmaceuticals Inc filed Critical Amylin Pharmaceuticals Inc
Application granted granted Critical
Publication of ATE491723T1 publication Critical patent/ATE491723T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT99906782T 1998-02-13 1999-02-05 Neue verbindungen mit gemischter amylin aktivität ATE491723T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7474698P 1998-02-13 1998-02-13
PCT/US1999/002603 WO1999040928A1 (en) 1998-02-13 1999-02-05 Novel mixed amylin activity compounds

Publications (1)

Publication Number Publication Date
ATE491723T1 true ATE491723T1 (de) 2011-01-15

Family

ID=22121450

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99906782T ATE491723T1 (de) 1998-02-13 1999-02-05 Neue verbindungen mit gemischter amylin aktivität

Country Status (8)

Country Link
EP (1) EP1053001B1 (de)
JP (1) JP4372345B2 (de)
AT (1) ATE491723T1 (de)
AU (1) AU766653B2 (de)
CA (1) CA2320962C (de)
DE (1) DE69943039D1 (de)
ES (1) ES2356595T3 (de)
WO (1) WO1999040928A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2422911A1 (en) * 2000-09-19 2002-03-28 Paul Fraser New inhibitors of iapp fibril formation and uses thereof
EP2123293A3 (de) 2000-12-14 2010-09-08 Amylin Pharmaceuticals, Inc. Peptid YY und Peptid YY-Agonisten zur Behandlung von Stoffwechselstörungen
EP1461068A4 (de) * 2001-11-26 2006-03-29 Protemix Corp Ltd Verfahren und zusammensetzungen zur normalisierung der lipidspiegel in säugergeweben
EP1663289A2 (de) * 2003-08-29 2006-06-07 Amylin Pharmaceuticals, Inc. Verfahren zur behandlung oder linderung von erkrankungen und störungen im zusammenhang mit ghrelin
ATE471340T1 (de) * 2004-02-11 2010-07-15 Amylin Pharmaceuticals Inc Peptide der amylin familie, verfahren zu deren herstellung und verwendung
JP6121992B2 (ja) * 2011-06-10 2017-04-26 ノヴォ ノルディスク アー／エス ポリペプチド
ES2640285T3 (es) * 2012-04-19 2017-11-02 Novo Nordisk A/S Análogos de amilina humana
KR102665710B1 (ko) 2017-08-24 2024-05-14 노보 노르디스크 에이/에스 Glp-1 조성물 및 그 용도
JP7761567B2 (ja) 2020-02-18 2025-10-28 ノヴォ ノルディスク アー／エス 医薬製剤

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3640042A1 (de) 1985-12-04 1987-06-11 Sandoz Ag Neue calcitoninderivate
NL8602950A (nl) 1985-12-04 1987-07-01 Sandoz Ag Calcitonine-derivaten en werkwijzen voor het bereiden van deze derivaten en van farmaceutische preparaten die ze bevatten.
NL194729C (nl) * 1986-10-13 2003-01-07 Novartis Ag Werkwijze voor de bereiding van peptidealcoholen via vaste fase.
DK163689A (da) * 1988-04-08 1989-10-30 Sandoz Ag Peptidderivater
US5321008A (en) 1991-01-10 1994-06-14 Amylin Pharmaceuticals, Inc. Methods and compositions for treatment of diabetes mellitus, hypoglycemia, and other conditions
US5580953A (en) * 1991-08-14 1996-12-03 Amylin Pharmaceuticals, Inc. Amylin antagonist peptides and uses therefor
US5506204A (en) 1991-11-19 1996-04-09 Peptech (Uk) Limited Muramyl compounds for treatment of septic shock
WO1993014408A1 (en) 1992-01-14 1993-07-22 Amylin Pharmaceuticals, Inc. Myotonin receptors and screening methods
US5376638A (en) * 1992-09-01 1994-12-27 Amylin Pharmaceuticals, Inc. Methods for treating renin-related disorders with amylin antagonists
US5625032A (en) 1993-07-21 1997-04-29 Amylin Pharmaceuticals, Inc. Selective amylin antagonist peptides and uses therefor
CZ69596A3 (en) * 1993-09-07 1997-06-11 Amylin Pharmaceuticals Inc Application of amylin, amylin agonist, amylin analog agonist or amylin antagonist for preparing a pharmaceutical preparation used for the control of gastrointestinal motility

Also Published As

Publication number Publication date
JP4372345B2 (ja) 2009-11-25
JP2002522355A (ja) 2002-07-23
CA2320962C (en) 2011-04-19
ES2356595T3 (es) 2011-04-11
DE69943039D1 (de) 2011-01-27
EP1053001A1 (de) 2000-11-22
EP1053001B1 (de) 2010-12-15
CA2320962A1 (en) 1999-08-19
WO1999040928A1 (en) 1999-08-19
EP1053001A4 (de) 2006-01-04
AU766653B2 (en) 2003-10-23
AU2661299A (en) 1999-08-30

Similar Documents

Publication Publication Date Title
DE69935229D1 (de) Neue antidiabetische peptide
MY134820A (en) Glucagon-like insulinotropic complexes, compositions and methods
DE69943039D1 (de) Neue verbindungen mit gemischter amylin aktivität
D'Alessio et al. Glucagon-like peptide 1: evolution of an incretin into a treatment for diabetes
IL144703A0 (en) Methods and reagents for treating glucose metabolic disorders
Rodbard et al. Adding fast‐acting insulin aspart to basal insulin significantly improved glycaemic control in patients with type 2 diabetes: a randomized, 18‐week, open‐label, phase 3 trial (onset 3)
BG104060A (en) Diabetes treatment with thiazolyidindion and methformine
NO20010982L (no) Fremgangsmåte for å administrere insulinotropiske peptider
MX9201110A (es) Composicion para el tratamiento de la diabetes mellitus, la hypoglicemia y de otros padecimientos relacionados.
Bolli et al. Lixisenatide, a novel GLP‐1 receptor agonist: efficacy, safety and clinical implications for type 2 diabetes mellitus
PL1751184T3 (pl) Białka fuzyjne FGF-21
CY1106971T1 (el) Συνεργητικη χρηση θειαζολιδινοδιονων με πεπτιδιο-1 που ομοιαζει με γλυκογονο και αγωνιστες αυτου για να θεραπευεται μη-ινσουλινο εξαρτωμενος διαβητης
UA92451C2 (en) Polyethelene glycol link glp-1 compounds
EA201101191A1 (ru) Фармацевтическая композиция, включающая ингибитор sglt-2, ингибитор дпп-iv и необязательно другой антидиабетический агент, и ее применение
GEP20033015B (en) Glucagon-Like Peptide-1 Improving Beta –Cell Response to Glucose in Subjects With Impaired Glucose Tolerance
EP1145717A3 (de) Synergistische Wirkung von einem Sulfonylharnstoff und/oder einem nicht Sulfonylharnstoff K-ATP Kanalblocker und einem cAMP-Phosphodiestrerase Typ 3 Inhibitor
DE602007007473D1 (en) 11-beta-hydroxysteroid-dehydrogenase-1-hemmer
NO940436D0 (no) Forlenget avgivelse av peptider
NO20015932D0 (no) Fremgangsmåte til å behandle diabetes
WO2005070444A8 (en) Methods for treating acute myocardial infarction by calcitonin gene related peptide and compositions containing the same
Lv et al. Comparison of a multiple daily insulin injection regimen (glargine or detemir once daily plus prandial insulin aspart) and continuous subcutaneous insulin infusion (aspart) in short‐term intensive insulin therapy for poorly controlled type 2 diabetes patients
Scelles et al. Plasminogen activator inhibitor 1 and insulin levels in various insulin resistance states.
WO2006136423A3 (en) Medicament for the treatment of impaired glucose metabolism
TW200630085A (en) Agents and methods for administration to the central nervous system
MX2025003293A (es) Florotaninos y alfa-fucanos para el tratamiento de la diabetes mellitus tipo 2

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties